Characterizing breast cancer subtypes using patient-derived organoids

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on developing tools to predict chemotherapy sensitivity in breast cancer patients, particularly those with triple-negative breast cancer or those experiencing relapse. By utilizing patient-derived organoids (PDO), which are 3D cultures that maintain the characteristics of primary tumors, the study aims to evaluate patient-specific responses to treatments. PDOs allow for pharmacological testing and genetic manipulation in a setting that closely mimics the human body, providing a platform for personalized therapy development. The goal is to create a stable collection of PDOs that represent the diversity of breast cancer subtypes, aiding in the understanding of chemoresistance and treatment efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* women diagnosed with primary BC, eligible for surgical resection of the tumor according to national and international guidelines.

age between 18 and 70 years; newly diagnosed breast neoplasms, tumor size of at least 1.5 cm diameter.

Exclusion Criteria:

breast cancer diagnosed during pregnancy, neoadiuvant chemotherapy

Where it's running

• IRCCS Fondazione Policlinico A. Gemelli
  Roma, Italy Recruiting

Study contacts

• Study coordinator: Alba Di Leone, Doc
• Email: alba.dileone@policlinicogemelli.it
• Phone: 0039 3474980503

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using organoids to test chemotherapy sensitivity in breast cancer patients

  This study is testing if lab-grown mini tumors from breast cancer patients can help predict how well they will respond to chemotherapy before treatment starts.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06155305

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.